Sign in Subscribe
Drugs

Genmab A/S Seeks Listings on Copenhagen and Frankfurt Stock Exchanges

Strategic Insights

— 1 min read

Genmab A/S, a biotechnology company specializing in developing fully human antibodies to treat various life-threatening and debilitating diseases, has announced plans to seek listings on the Copenhagen and Frankfurt stock exchanges in October 2000. The company, founded in February 1999 through a joint effort between Medarex and Danish investors, has a two-pronged strategy to maximize the value of its antibody development capabilities. Genmab aims to move from genomics to products by developing antibodies to novel disease targets and to create a large and diverse portfolio of antibody products.

Key Takeaways:

  • Genmab A/S is a biotechnology company focusing on developing fully human antibodies for various diseases.
  • The company has announced plans to seek listings on the Copenhagen and Frankfurt stock exchanges in October 2000.
  • Genmab's two-pronged strategy involves moving from genomics to products by developing antibodies to novel disease targets and creating a large and diverse portfolio of antibody products.
  • The company has four products in development, with HuMax(TM)-CD4 completing a Phase I/II study for rheumatoid arthritis treatment.
  • Genmab has corporate collaborations with Medarex, Inc., Immunex Corporation, Eos Biotechnology, Inc., and Oxford GlycoSciences Plc.
  • The company has access to novel genomics targets through its alliances and has recently completed a $40.5 Million private placement, led by Index Ventures.
  • Genmab's CEO, Lisa N. Drakeman, believes the company's two-pronged strategy will allow it to expand its growing therapeutic product pipeline.

Statistics:

  • Genmab A/S was founded in February 1999.
  • The company has four products in development, with HuMax(TM)-CD4 completing a Phase I/II study.
  • The private placement raised $40.5 Million, led by Index Ventures.
  • Genmab aims to create a large and diverse portfolio of antibody products.

Sources:

  • Genmab A/S, press release, September 11, 2000.
  • "Genmab to List on Copenhagen and Frankfurt Stock Exchanges," PR Newswire, September 11, 2000.

Read more